Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (1-10 of 336) with videos related to

Pageof 34
Sort By:
JAMA|February 3, 2011
Bevacizumab treatment for solid tumors: boon or bust?Daniel F Hayes
Breast (Edinburgh, Scotland)|November 17, 2009
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?Daniel F Hayes
The New England Journal of Medicine|June 15, 2007
Clinical practice. Follow-up of patients with early breast cancerDaniel F Hayes
The New England Journal of Medicine|October 14, 2011
Steady progress against HER2-positive breast cancerDaniel F Hayes
Breast (Edinburgh, Scotland)|October 1, 2013
From genome to bedside: are we lost in translation?Daniel F Hayes
The New England Journal of Medicine|September 11, 2019
HER2 and Breast Cancer - A Phenomenal Success StoryDaniel F Hayes
Molecular Oncology|December 3, 2014
Biomarker validation and testingDaniel F Hayes
Journal of Oncology Practice|January 14, 2016
Is Breast Cancer a Curable Disease?Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's ViewpointDaniel F Hayes
The New England Journal of Medicine|January 9, 2020
Progress in the Treatment of Breast Cancer. ReplyDaniel F Hayes
Pageof 34

Showing results (1-10 of 336) with videos related to

Sort By:
Pageof 34
JAMA|February 3, 2011
Bevacizumab treatment for solid tumors: boon or bust?Daniel F Hayes
Breast (Edinburgh, Scotland)|November 17, 2009
Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?Daniel F Hayes
The New England Journal of Medicine|June 15, 2007
Clinical practice. Follow-up of patients with early breast cancerDaniel F Hayes
The New England Journal of Medicine|October 14, 2011
Steady progress against HER2-positive breast cancerDaniel F Hayes
Breast (Edinburgh, Scotland)|October 1, 2013
From genome to bedside: are we lost in translation?Daniel F Hayes
The New England Journal of Medicine|September 11, 2019
HER2 and Breast Cancer - A Phenomenal Success StoryDaniel F Hayes
Molecular Oncology|December 3, 2014
Biomarker validation and testingDaniel F Hayes
Journal of Oncology Practice|January 14, 2016
Is Breast Cancer a Curable Disease?Daniel F Hayes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's ViewpointDaniel F Hayes
The New England Journal of Medicine|January 9, 2020
Progress in the Treatment of Breast Cancer. ReplyDaniel F Hayes
Pageof 34